Which has higher earnings & valuation, NYXH or PROF?

Profound Medical has higher revenue and earnings than Nyxoah. Profound Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 6.02 -$101.92M -$2.52 N/A Profound Medical $16.10M 15.43 -$42.57M -$0.98 N/A

Is NYXH or PROF more profitable?

Profound Medical has a net margin of -171.57% compared to Nyxoah's net margin of -443.16%. Profound Medical's return on equity of -63.03% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Profound Medical -171.57% -63.03% -51.24%

Does the media prefer NYXH or PROF?

In the previous week, Profound Medical had 2 more articles in the media than Nyxoah. MarketBeat recorded 6 mentions for Profound Medical and 4 mentions for Nyxoah. Profound Medical's average media sentiment score of 0.70 beat Nyxoah's score of 0.33 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NYXH or ZJYL?

Nyxoah presently has a consensus target price of $4.26, suggesting a potential upside of 142.16%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, NYXH or ZJYL?

Jin Medical International has higher revenue and earnings than Nyxoah. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 6.02 -$101.92M -$2.52 N/A Jin Medical International $20.69M 8.15 $1.19M N/A N/A

Which has preferable earnings & valuation, STIM or NYXH?

Neuronetics has higher revenue and earnings than Nyxoah. Neuronetics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.39 -$39M -$0.44 N/A Nyxoah $11.33M 6.02 -$101.92M -$2.52 N/A

Is STIM or NYXH more profitable?

Neuronetics has a net margin of -19.62% compared to Nyxoah's net margin of -443.16%. Neuronetics' return on equity of -125.11% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% Nyxoah -443.16% -178.90% -81.83%

Does the media prefer STIM or NYXH?

In the previous week, Nyxoah had 3 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for Nyxoah and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat Nyxoah's score of 0.33 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nyxoah 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, PDEX or NYXH?

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $74.64M 2.64 $8.98M $3.62 17.06 Nyxoah $11.33M 6.02 -$101.92M -$2.52 N/A

Is PDEX or NYXH more profitable?

Pro-Dex has a net margin of 16.08% compared to Nyxoah's net margin of -443.16%. Pro-Dex's return on equity of 22.78% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% Nyxoah -443.16% -178.90% -81.83%

Does the media refer more to PDEX or NYXH?

In the previous week, Nyxoah had 2 more articles in the media than Pro-Dex. MarketBeat recorded 4 mentions for Nyxoah and 2 mentions for Pro-Dex. Nyxoah's average media sentiment score of 0.33 beat Pro-Dex's score of 0.00 indicating that Nyxoah is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nyxoah 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NYXH or CNXU?

In the previous week, Nyxoah and Nyxoah both had 4 articles in the media. Conexeu Sciences' average media sentiment score of 0.80 beat Nyxoah's score of 0.33 indicating that Conexeu Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Conexeu Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nyxoah (NYXH) Competitors

$1.76 +0.25 (+16.56%)

As of 09/3/2026 04:00 PM Eastern

Compare

NYXH vs. PROF, ZJYL, STIM, PDEX, and CNXU

Should you buy Nyxoah stock or one of its competitors? Nyxoah's main competitors and comparable companies include Profound Medical (PROF), Jin Medical International (ZJYL), Neuronetics (STIM), Pro-Dex (PDEX), and Conexeu Sciences (CNXU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nyxoah compare to Profound Medical?

Nyxoah (NASDAQ:NYXH) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Nyxoah has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Profound Medical has a net margin of -171.57% compared to Nyxoah's net margin of -443.16%. Profound Medical's return on equity of -63.03% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Profound Medical	-171.57%	-63.03%	-51.24%

In the previous week, Profound Medical had 2 more articles in the media than Nyxoah. MarketBeat recorded 6 mentions for Profound Medical and 4 mentions for Nyxoah. Profound Medical's average media sentiment score of 0.70 beat Nyxoah's score of 0.33 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Profound Medical shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profound Medical has higher revenue and earnings than Nyxoah. Profound Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	6.02	-$101.92M	-$2.52	N/A
Profound Medical	$16.10M	15.43	-$42.57M	-$0.98	N/A

Nyxoah presently has a consensus price target of $4.26, suggesting a potential upside of 142.16%. Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 69.12%. Given Nyxoah's higher probable upside, equities research analysts clearly believe Nyxoah is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Profound Medical beats Nyxoah on 12 of the 17 factors compared between the two stocks.

How does Nyxoah compare to Jin Medical International?

Nyxoah (NASDAQ:NYXH) and Jin Medical International (NASDAQ:ZJYL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Nyxoah has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.31, meaning that its stock price is 631% more volatile than the broader market.

Nyxoah presently has a consensus target price of $4.26, suggesting a potential upside of 142.16%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jin Medical International has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Jin Medical International's return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Jin Medical International	N/A	N/A	N/A

In the previous week, Nyxoah had 4 more articles in the media than Jin Medical International. MarketBeat recorded 4 mentions for Nyxoah and 0 mentions for Jin Medical International. Nyxoah's average media sentiment score of 0.33 beat Jin Medical International's score of 0.00 indicating that Nyxoah is being referred to more favorably in the media.

Company	Overall Sentiment
Nyxoah	Neutral
Jin Medical International	Neutral

Jin Medical International has higher revenue and earnings than Nyxoah.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	6.02	-$101.92M	-$2.52	N/A
Jin Medical International	$20.69M	8.15	$1.19M	N/A	N/A

Summary

Jin Medical International beats Nyxoah on 7 of the 12 factors compared between the two stocks.

How does Nyxoah compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Neuronetics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Neuronetics has a net margin of -19.62% compared to Nyxoah's net margin of -443.16%. Neuronetics' return on equity of -125.11% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Nyxoah	-443.16%	-178.90%	-81.83%

In the previous week, Nyxoah had 3 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for Nyxoah and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat Nyxoah's score of 0.33 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nyxoah	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuronetics has higher revenue and earnings than Nyxoah. Neuronetics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.39	-$39M	-$0.44	N/A
Nyxoah	$11.33M	6.02	-$101.92M	-$2.52	N/A

53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Neuronetics presently has a consensus target price of $4.50, suggesting a potential upside of 65.44%. Nyxoah has a consensus target price of $4.26, suggesting a potential upside of 142.16%. Given Nyxoah's higher possible upside, analysts plainly believe Nyxoah is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Neuronetics beats Nyxoah on 10 of the 16 factors compared between the two stocks.

How does Nyxoah compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Pro-Dex has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

In the previous week, Nyxoah had 2 more articles in the media than Pro-Dex. MarketBeat recorded 4 mentions for Nyxoah and 2 mentions for Pro-Dex. Nyxoah's average media sentiment score of 0.33 beat Pro-Dex's score of 0.00 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nyxoah	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 16.08% compared to Nyxoah's net margin of -443.16%. Pro-Dex's return on equity of 22.78% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
Nyxoah	-443.16%	-178.90%	-81.83%

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$74.64M	2.64	$8.98M	$3.62	17.06
Nyxoah	$11.33M	6.02	-$101.92M	-$2.52	N/A

Pro-Dex currently has a consensus target price of $70.00, suggesting a potential upside of 13.36%. Nyxoah has a consensus target price of $4.26, suggesting a potential upside of 142.16%. Given Nyxoah's higher possible upside, analysts clearly believe Nyxoah is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Pro-Dex beats Nyxoah on 10 of the 16 factors compared between the two stocks.

How does Nyxoah compare to Conexeu Sciences?

Nyxoah (NASDAQ:NYXH) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Nyxoah currently has a consensus price target of $4.26, suggesting a potential upside of 142.16%. Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 279.51%. Given Conexeu Sciences' higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Conexeu Sciences has lower revenue, but higher earnings than Nyxoah. Conexeu Sciences is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	6.02	-$101.92M	-$2.52	N/A
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A

In the previous week, Nyxoah and Nyxoah both had 4 articles in the media. Conexeu Sciences' average media sentiment score of 0.80 beat Nyxoah's score of 0.33 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Conexeu Sciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Conexeu Sciences has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Conexeu Sciences' return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Conexeu Sciences	N/A	N/A	N/A

Summary

Conexeu Sciences beats Nyxoah on 7 of the 11 factors compared between the two stocks.

Get Nyxoah News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NYXH vs. The Competition

Export

Metric	Nyxoah	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.53M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.70	25.92	273.29	25.38
Price / Sales	6.02	73.28	613.45	92.55
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	0.71	6.04	12.89	6.14
Net Income	-$101.92M	$150.03M	$3.47B	$349.01M
7 Day Performance	10.00%	-1.32%	0.60%	-0.27%
1 Month Performance	21.38%	1.27%	5.73%	0.68%
1 Year Performance	-69.12%	9.88%	25.35%	14.84%

Nyxoah Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NYXH Nyxoah	2.7788 of 5 stars	$1.76 +16.6%	$4.26 +142.2%	-70.1%	$58.53M	$11.33M	N/A	110	News Coverage Positive News High Trading Volume
PROF Profound Medical	2.0945 of 5 stars	$6.81 +0.1%	$11.50 +68.9%	+56.0%	$247.12M	$16.10M	N/A	150
ZJYL Jin Medical International	N/A	$2.77 -8.9%	N/A	-83.4%	$238.43M	$20.69M	N/A	245	Gap Up
STIM Neuronetics	4.0279 of 5 stars	$2.98 +3.1%	$4.50 +51.0%	-16.8%	$220.21M	$149.16M	N/A	180	Positive News
PDEX Pro-Dex	1.3069 of 5 stars	$65.22 -2.5%	$70.00 +7.3%	+32.9%	$213.47M	$66.59M	18.02	140	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NYXH) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nyxoah (NYXH) Competitors

NYXH vs. PROF, ZJYL, STIM, PDEX, and CNXU

How does Nyxoah compare to Profound Medical?

Summary

How does Nyxoah compare to Jin Medical International?

Summary

How does Nyxoah compare to Neuronetics?

Summary

How does Nyxoah compare to Pro-Dex?

Summary

How does Nyxoah compare to Conexeu Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nyxoah (NYXH) Competitors

NYXH vs. PROF, ZJYL, STIM, PDEX, and CNXU

How does Nyxoah compare to Profound Medical?

Which has more volatility & risk, NYXH or PROF?

Is NYXH or PROF more profitable?

Does the media prefer NYXH or PROF?

Do institutionals and insiders have more ownership in NYXH or PROF?

Which has higher earnings & valuation, NYXH or PROF?

Do analysts rate NYXH or PROF?

Summary

How does Nyxoah compare to Jin Medical International?

Which has more risk and volatility, NYXH or ZJYL?

Do analysts prefer NYXH or ZJYL?

Is NYXH or ZJYL more profitable?

Does the media refer more to NYXH or ZJYL?

Which has stronger valuation and earnings, NYXH or ZJYL?

Summary

How does Nyxoah compare to Neuronetics?

Which has more risk and volatility, STIM or NYXH?

Is STIM or NYXH more profitable?

Does the media prefer STIM or NYXH?

Which has preferable earnings & valuation, STIM or NYXH?

Do insiders & institutionals have more ownership in STIM or NYXH?

Do analysts prefer STIM or NYXH?

Summary

How does Nyxoah compare to Pro-Dex?

Which has more risk & volatility, PDEX or NYXH?

Does the media refer more to PDEX or NYXH?

Is PDEX or NYXH more profitable?

Do institutionals & insiders hold more shares of PDEX or NYXH?

Which has preferable valuation and earnings, PDEX or NYXH?

Do analysts prefer PDEX or NYXH?

Summary

How does Nyxoah compare to Conexeu Sciences?

Do analysts rate NYXH or CNXU?

Which has preferable valuation and earnings, NYXH or CNXU?

Does the media prefer NYXH or CNXU?

Is NYXH or CNXU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools